Jonathan Wolf

💡 Investment Announcement At the Conduit EIS Impact Fund, our 100-Year Life thesis drives us to back ventures that help people healthier, and more fulfilling lives for longer. We are thrilled to announce Conduit Connect's latest investment in Gladys, an AI-powered home care platform on a mission to fix Britain’s broken care system. Founded by George Robinson and Alex Sorisi, Gladys combines smart technology, logistics know-how, and a relentless focus on better outcomes for both families and carers. The platform matches people in need of support with the UK’s best local carers — offering 5-star care at fairer prices, while helping carers earn up to 65% more than traditional agencies. As George Robinson puts it: “We all know that Britain’s care system is broken. Re-arranging deck-chairs on a sinking ship will not cut it. People are dying unnecessarily, and brilliant carers are undervalued and underpaid. Gladys is using this investment to supercharge its technology, and deliver the service that we would want for our loved ones.” Gladys has already supported tens of thousands of hours of independent living across a 20,000 km area. With this new funding — part of a £1.5m Seed round led by Cornerstone VC — Gladys aims to expand nationwide, delivering hundreds of thousands of hours of quality care by 2026. We believe technology can help rebuild trust and dignity in care — creating meaningful, well-paid work and ensuring that people receive the support they deserve long before they get sick. Rodney Appiah Paolo Pio Exceptional Ventures Gabrielle Morgan Gemma Lakin Conduit Connect The Conduit EIS Impact Fund The Conduit Adam Lawrence #ImpactInvesting #EIS #HealthTech #AIforGood #CareInnovation #ConduitImpactFund #FutureOfCare #StartupInvestment

64

5 Comments

Very excited to share that Plural is leading a $60 million Series A in CoMind, the startup building breakthrough optical sensing technology to revolutionise brain monitoring and treatment. For decades, doctors treating critically ill patients have been forced to compromise when monitoring the brain. Today's approaches use risky, expensive, highly invasive procedures that require drilling a hole into a patient's skull, or rely on inaccurate non-invasive monitoring that can compromise treatment decisions. To take just one example of why this matters, in the US alone 3 million patients suffer traumatic brain injuries (TBIs) every year, but only 5% receive an intracranial pressure test, which requires drilling a hole in the skull and carries a 15% complication rate. The rest are treated with limited information, leading to worse data, worse outcomes and higher costs. London-based CoMind is changing that. Its optical neuromonitoring platform can non-invasively measure three core brain health indicators - cerebral blood flow, autoregulation and intracranial pressure - something that has never been done before. It’s a breakthrough that could help tens of millions of patients worldwide and redefine how we understand and treat the brain. The company is led by a true outlier of a young founder, James Dacombe. He started programming when he was 13 and founded CoMind when he was just 17. His work ethic and rapid learning rate have led him to build a working product and take it through two successful clinical research studies, with the help of a stellar leadership team of medical and industry veterans from the likes of Medtronic, Tufts Medical Center and UCL.  This is only the beginning. CoMind plans to expand its product portfolio to measure additional physiological parameters and develop CoVision, an AI platform that transforms sensor data into predictive insights, identifying complications early and personalising treatment. The company aims to gain regulatory approval within two years, unlocking access to the huge ICU market in the US. And while this first sensor can revolutionise TBI monitoring, a second device is already in development to measure more parameters and treat more brain conditions. This technology has the potential to dramatically improve how we monitor our brains, giving doctors better information and more choices for treating patients, while building out a whole new market by providing a far more affordable and safe alternative to existing solutions. Read more about why we invested in CoMind here: https://lnkd.in/e-NPgDVp And Tim Bradshaw’s write up in today’s Financial Times here: https://lnkd.in/eAynvqPF

266

13 Comments

This mirrors what we are seeing in the European MedTech and HealthTech M&A Markets, Series A and B are becoming M&A Off Ramps as HealthTech Startups struggle to raise .. Ngai Yeung

2